A B S T R A C T A 34-year-old Black wom-an had severe megaloblastic anemia in childhood. Initially, and over the years, she responded well to miassive doses of parenteral cobalamin (Cbl) 
INTRODUCTION
A patient, a Black woman born in 1944 and described previously (1) , presented herselfat the age of 12 yr with multiple superficial mouth ulcers, pancytopenia, and megaloblastic anemia. Two sisters allegedly died of similar illness at ages 5 and 12, respectively. The patient had free acid in the gastric juice, a normal Schilling test, performed twice, 20 yr apart, and an increased serum level of cobalamin (Cbl)' and a normal serum level of folate during relapse. She responded to pharThis work was presented in part at the Annual Meeting of the American Society of Hematology, Boston, Mass., 4 and 6 December 1976.
Received for publication 8 May 1978 and in revised form 9 July 1979. 'Abbreviations used in this paper: apo, apoprotein; Cbl, cobalamin; PHA, phytohemagglutinin; TC II, transcobalamin II. macologic doses of either Cbl or folic acid. For a 10-yr period she received folic acid without developing evidence of posterior and lateral column degeneration of the spinal cord.
Because of repeatedly elevated levels of serum Cbl during relapse, studies of serum R binders, transcobalamin II (TC II) and cellular uptake of Cbl bound to TC II were undertaken. This paper reports the results of these studies, which demonstrate in this patient the presence of a TC II of poor function. We will refer to this variant Cbl binding protein as "TC II Cardeza."
METHODS
Assay of folate enzytnes atnd related ancalyses. Serum folate and Cbl were determined by microbiologic (2, 3) and radioassay (4) methods, respectively. Amino acid analyses of plasma or urine, determiination of urinary methylmalonic acid, and assay of plamsa or urinary cystathionine and homocystine were performed according to published methods (5) during relapse, as confirmed by a megaloblastic bone marrow. Urinary formiminoglutamic acid was determined during relapse by the cellulose-acetate electrophoresis method (6) . The following folate enzyme levels were determined during remission and relapse: dihydrofolic acid reductase (7), formate-activating enzyme (8) , cylcohydrolase (9) , 5,10 methylene tetrahydrofolic acid reductase (10) , serine hydroxymethyl transferase (11) , and thymidylate synthetase (12) . Peripheral leukocytes were used for the assay of all these enzymes except thymidylate synthetase, for which phytohemagglutinin (PHA)-stimulated lymphocytes were used. Protein was measured by the method of Lowry et al. (13) .
Measurements of serum Cbl binding proteins. Serum collected from the patient was frozen once and then thawed without raising the temperature above 4°C, immediately separated into small aliquots, and then frozen. It was kept at -20°C until use. Total serum TC II and R binders were measured by radioimmunoassay (14, 15) . Total serum Cbl and its division between TC II and R binders were measured by an isotope dilution assay (16) . The TC II-Cbl was separated before assay by fractionation with 1.96 M (NH4)2SO4 (15, 16) . The unsaturated Cbl binding capacity was determined by saturating the apoprotein (apo) TC II and serum R with radioactive Cbl and then separating the TC II from the serum R binders by both Sephadex G-200 (Pharmacia Fine Chemicals, Inc., Piscataway, N. J.) gel filtration (17) and (NH4)2SO4. Gel filtration was used to evaluate the patient's TC II and to detect any potential TC II-antibody complex. 1 ml of the patient's serum was labeled with 2.565 ng of CN[57Co]Cbl, 20% over unsaturated CbI binding capacity, and separated on Sephadex G-200. The void volume was marked with blue dextran (Pharmacia Fine Chemicals, Inc.). The column had been previouisly calibrated by fractionation of labeled normal serum R-type binders and TC II. An aliquot of the TC II-Cbl obtained by gel filtration was concentrated (Amicon PM-10 ultrafiltration membrane, Amicon Corp., Scientific Sys. Div., Lexington, Mass.) and allowed to react with a 10-fold excess of rabbit antihuman TC 11 (30 min at 37°C, and then 17 h at 40C) and then filtered through a second Sephadex G-200 column. A shift of the labeled TC II to the void volume was indicative of coupling with anti-TC II.
Cellular uptake of Cbl botund to TC II. The activity of the patient's TC II in the promotion of Cbl uptake by HeLa cells was studied in two ways. The first was the standard form of such studies in which uptake of CN[57Co]Cbl is detected (18) . Before the study, the holo TC II and apo TC II of both the patients and control sera were measured as above. For each experiment, all apo TC II was converted to holo TC II with CN[5'Co]Cbl of appropriate specific activity. 3 x 106 cells were exposed during culture to amounts of whole serum that contained 2.0 ng of holo TC II, part of which was radioactive. Any R-Cbl in the seruim can be ignored because HeLa cells do not take up R-Cbl. After a 3-h culture at 37°C in medium M-199 (Microbiological Associates, Inc., Walkersville, Md.), the cells were harvested, washed three times, and the radioactivity was counted. Uptake, while detected by the radioactivity, was calculated on the basis of the total TC II-Cbl taken up, which was in part TC II-CN[57Co]Cbl, and the remainder Cbl of various forms bound naturally to the serum TC II. There were several variations of this basic technique in a search for inhibitors ofTC 1I-Cbl in the patient's serum. Experiments were condlucted in duplicate.
In the unlikely event that CN[57Co]Cbl bound to TC II reacts differently than Cbl carried naturally, a second approach was applied for confirmation. The principle of the experiment was the uptake of the Cbl naturally bound to TC II, the end point being bioassay of the lysed HeLa cells by Euglena gracilis (16) . One control serum and TC II-Cbl partially purified from Cohn fraction III were handled the same way as the patient's. Before the study, the amounts of holo and apo TC II were measured for each source of TC II. 1.0-1.3 X 106 HeLa cells were exposed to 1.0 ng of TC 1I-Cbl for 3 h at 37°C. The cells were harvested, washed, and assayed for total Cbl content. Included were cells not exposed to added Cbl of any sort; their content was subtracted from the experimental values to obtain the amount of TC II-Cbl uptake. Variants of the basic technique are given below. Experiments were conducted in duplicate.
The uptake of CN[57Co]Cbl bound to normal or patient's TC II, by PHA-stimulated human lymphocytes was studied by using slightly modified published techniques (19) . TC II from normal serum and from the patient's serum was prepared by ammonium sulfate precipitation and dialysis. Holo, apo, and total TC II were measured as described above. Because the concentration of the added radioactive Cbl was known, the amount of total Cbl uptake by the lymphocytes could be determined. Human lymphocytes from normal individuals and once from the patient were separated and cultured with PHA for 3 d. The incubation mixture in duiplicate consisted of 1 ml of stimulated lymphocytes (5 x 106 cells) in medium M-199 and 0.5 ml of the patient's TC II or normal TC II, each containing CN[57Co]Cbl. The final volume was adjusted to 3 ml with the same medium, and the incubation was carried out for 1 or 3 h at 4°C or 37°C. The concentration of Cbl in the incubation mixture varied from 0.25 to 1.0 ng. The lymphocytes were washed three times with saline, lysed with water, and their radioactivity measured. A saturation study using various concentrations of the patient's TC II and of a normal TC II were done to determine whether or not the patient's defective TC II might not facilitate transport into cells when used at higher concentrations. The concentration of TC II tused varied from 0.25 to 5.0 ng/3 ml vol that contained 5 x 106 stiuntilated lymphocytes. The cells were incubated at 37°C for 3 h. In the mixing experiments, for detection of inhibitors, the patient's isolated nonradioactive TC II was incubated with the stimuilated lymphocytes for 0.5 h before the addition of normal TC II-CN[57Co]Cbl. After an incubation period of 1 h at 37°C, the cells were washed three times, lysed, ancl then their radioactivity was measured.
Clearance of TC II in the rabbit (20) . The TC II of normal serulm or the patient's serum after satuiration with radioactive Cbl was isolated by ammonituin sulfate precipitation, dialysed, and subjected to Sephadex G-200 gel filtration. The TC II radioactive fractions were pooled and then concentrated to a voltume of 3-5 ml by Amicon PM-10 ultrafiltration membranes.
Each rabbit was anesthetized with 75 mg of Nembutial (Abbott Laboratories, North Chicago, Ill.), given intravenously with 500 U of heparin. This was followed by an injection of' 10-15 ng oftTC II-Cbl, partly radioactive, in a voltume of2-4 ml. 4 ml of blood specimens (four to six in number) were collected by cardiac punctuire over 60-100 min. (It was not always possible to keep the schedule of 10, 20, 30, 45, 60, and 100 min.) Plasma was separated, the radioactivity measured, and the data plotted on a semilog paper to determine the t112 of TC II-CIA clearance.
RESULTS
Assay offolate enzymes and related analysis. During relapse, the serum levels of folic acid varied between 6.0 and 11.5 ng/ml (normal: 1.9-14.0), whereas the serum levels of Cbl varied between 2,500 and 5,000 pg/ml (normal: 200-1,100). Over the years, the serum Cbl levels were determined by the bioassay method as well as by the radioimmunoassay method, and the results were not significantly different. As the patient went into relapse after cessation of folic acid therapy, seruim Cbl levels decreased, albeit still remaining high.
The folate-related enzymes of the patient's peripheral blood leukocytes were normal except for thymidylate synthetase. increased and 60% saturated with Cbl in contrast to -10% saturation of normal sera. Fig. la shows that the labeled apo TC II had the same gel filtration properties as normal TC II, and there was no evidence of any unusual Cbl binding protein or of a circulating complex that contained normal binders. Fig. lb shows that the patient's TC II-Cbl reacted with antibody against normal human TC II in a normal fashion.
The TC II of the patient while increased was able to bind Cbl in vivo and in vitro. It behaved like normal TC II by gel filtration and in (NH4)2SO4 solubility and was immunologically competent by two systems of evaluation.
Uptake of TC II-Cbl by two systems. (22) and are depicted in Table IV . The results are expressed in geometric mean with the coefficient of variation in parenthesis. The latter was high in one subgroup (patient at 37°C) because it included three low values, each 0.3. Two-way analysis ofthe variance (with correction for disproportionate numbers in the subgroups) and with log transformation to help equalize intragroup variances, draws the following conclusions: No significant interaction between temperature and disease status, no significant difference between 1 and 3 h of incubation, highly significant difference between control and patient (control, 7.5 times as big as patient, P < 0.001), and highly significant difference between 40 and 37°C when control and patient values are combined (37°C, 2.2 times as big as 4°C, P < 0.01). Again, in this system, the patient's TC II did not interfere with the function of normal TC II in facilitating the uptake of Cbl by the PHA-stimulated lymphocytes. In addition, the patient's TC II did not interfere with the function of normal TC II in facilitating the uptake of Cbl by these cells, even though larger amounts of the patient's TC II were used than in the previous study (HeLa cells). In this experiment, the uptake of normal radioactive TC II-Cbl after incubation of the stimulated lymphocytes (5 x 106 cells) with patient's nonradioactive TC II-Cbl for 0.5 h was 9.8 and 10.8 pg (compared with a control of 10.0 and 10.5). Fig. 2 depicts the effect of increasing concentration of patient or normal TC II on uptake. At a concentration of 5.0 ng of TC II-Cbl, in the incubation mixture, the uptake of Cbl by the lymphocytes passed the maximum for both patient or control.
When the patient's own stimulated lymphocytes (5 x responds to large and fre(uent injections of Cbl (26) (27) (28) . In addition, these patients have been prone to infection (decreased production of iinmunoglobulin, in one case), have had poor intestinal absorption of Cbl, and have had a rapid rate of relapse after discontinuation of Cbl therapy. Our patient had similar, but not idenitical, clinical and hematologic findings. The onset of anemia in our patient was delayed, perhaps suggesting that in time the TC II-Cbl receptors of the bone marrow cells changed in configuration and became more specific and discriminatory to the structure of TC II. The family history of the patient suggested a familial rather than a mutational abnormality. The fact that the patient's TC II could bind Cbl could explain the normal intestinal absorption of the vitamin. In addition, the patient was not prone to infection, and the rate of relapse after cessation of CIA but not folate therapy was fast.
Our patient suffered the lack of Cbl only in tissues of rapidly dividing cells (bone marrow and gastrointestinal). The two well-known reactions in which CIl acts as coenzyme were not affected in our patient, which suggested that these reactions could be divorced from the megaloblastic development. In these two reactions, methyl CIl is a cofactor in the methylation of homocysteine to methionine (29) and adenosyl Cbl is a cofactor in the isomerization of methylinaloniic acid CoA (30) . Conse(luently, in Cbl deficiency there is homocystinemia, cystathioninuria, severe hypomethioninemia (0.07 mg/dl) and methylmalonic aciduria (4, 31, 32 diminished level of methionine (0.22 mgldl) and other branched amino acids could have been a reflection of anorexia and diminished food intake during relapse. These findings suggest that the two known Cbl-dependent reactions occur primarily or predominantly in tissues in which the mechanism for the uptake of Cbl may be different from that of the bone marrow. The increased amounts of TC II in our patient could bind Cbl and react with specific antibody but could not facilitate the uptake of the vitamin, which is analogous to the abnormal human intrinsic factor that could bind but could not facilitate the intestinal absorption of the vitamin (33) . The uptake of TC 11-Cbl was tested in two systems: HeLa cells and stimulated lymphocytes. The patient's TC II did not facilitate the uptake of Cbl, nor did it interfere with the function of normal TC II-Cbl. The observation that the uptake of patient's TC II-Cbl was also low at 40C suggests that the abnormal TC IICbl could not bind to the specific cell receptors (25) . The patient's own stimulated lymphocytes took up normal TC II-Cbl but not that of the patient's, which indicates that the defect was not at the level of the patient's uptake mechanism. The clearance of the patient's TC II-Cbl from the rabbit's circulation was similar to that of normal human TC II-Cbl. Apparently, the structural difference between the patient's TC II and normal TC II was not recognized by the rabbit tissues. However, more studies are needed to confirm this view.
